Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.

The US Food and Drug Administration (FDA) Expanded Access (EA) Program, which allows for compassionate uses of unapproved therapeutics and diagnostics outside of clinical trials, has gained significant traction during the Coronavirus 2019 (COVID-19) pandemic. While development of vaccines has been t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Drug Discov Today
Päätekijät: Rizk, John G., Forthal, Donald N., Kalantar-Zadeh, Kamyar, Mehra, Mandeep R., Lavie, Carl J., Rizk, Youssef, Pfeiffer, JoAnn P., Lewin, John C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier Ltd. 2021
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7694556/
https://ncbi.nlm.nih.gov/pubmed/33253920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2020.11.025
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia